BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 23792191)

  • 1. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
    Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
    Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutics: Embracing instability.
    McCarthy N
    Nat Rev Cancer; 2013 Aug; 13(8):521. PubMed ID: 23842643
    [No Abstract]   [Full Text] [Related]  

  • 3. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
    Otto T; Horn S; Brockmann M; Eilers U; Schüttrumpf L; Popov N; Kenney AM; Schulte JH; Beijersbergen R; Christiansen H; Berwanger B; Eilers M
    Cancer Cell; 2009 Jan; 15(1):67-78. PubMed ID: 19111882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
    Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
    Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
    Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
    Richards MW; Burgess SG; Poon E; Carstensen A; Eilers M; Chesler L; Bayliss R
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13726-13731. PubMed ID: 27837025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
    Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
    Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
    J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
    Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
    ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.
    Liu Y; Hawkins OE; Su Y; Vilgelm AE; Sobolik T; Thu YM; Kantrow S; Splittgerber RC; Short S; Amiri KI; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    EMBO Mol Med; 2013 Jan; 5(1):149-66. PubMed ID: 23180582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma.
    Maris JM
    Cancer Cell; 2009 Jan; 15(1):5-6. PubMed ID: 19111875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.
    Shang X; Burlingame SM; Okcu MF; Ge N; Russell HV; Egler RA; David RD; Vasudevan SA; Yang J; Nuchtern JG
    Mol Cancer Ther; 2009 Aug; 8(8):2461-9. PubMed ID: 19671766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugging MYCN through an allosteric transition in Aurora kinase A.
    Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
    Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
    Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
    Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
    Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.